Abstract
OBJECTIVE: The GIANT study collected information on patients with acute exacerbations of chronic bronchitis (AECB) and chronic obstructive pulmonary disease (COPD) and the effect of treatment with moxifloxacin. METHODS: AECB history, concomitant diseases, moxifloxacin treatment, concomitant medication, clinical symptoms and adverse events were recorded. A questionnaire at the end of treatment recorded the impact on patients' daily lives. RESULTS: Among 9225 patients from eight European countries, marked variation was seen in characteristics including age, smoking history and type of exacerbation. Spirometry use was more common among chest physicians (66.7%) than GPs (15.5%). Patients with Anthonisen type 1 and 2 exacerbations had more frequent exacerbations and these patients experienced a greater impact on daily activities compared with patients with type 3 episodes. Patient symptoms improved with moxifloxacin treatment after a mean (SD) of 3.4 (1.8) days, allowing return to normal daily activities after 5.4 (4.4) days and with full recovery taking 6.5 (3.1) days. CONCLUSIONS: Characteristics of patients with AECB and acute exacerbations of COPD differ among European countries. Spirometry is under-used, particularly in primary care and antibiotic treatment does not always follow current guidelines. Results confirm the efficacy of moxifloxacin in the treatment of AECB in real-life conditions.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 267-277 |
| Number of pages | 11 |
| Journal | Therapeutic Advances in Respiratory Disease |
| Volume | 3 |
| Issue number | 6 |
| State | Published - Dec 2009 |
Fingerprint
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
- Pharmacology (medical)
Cite this
Characterisation of exacerbations of chronic bronchitis and COPD in Europe : the GIANT study. / Miravitlles, Marc; Anzueto, Antonio R; Ewig, Santiago; Legnani, Delfino; Stauch, Kathrin.
In: Therapeutic Advances in Respiratory Disease, Vol. 3, No. 6, 12.2009, p. 267-277.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Characterisation of exacerbations of chronic bronchitis and COPD in Europe
T2 - the GIANT study.
AU - Miravitlles, Marc
AU - Anzueto, Antonio R
AU - Ewig, Santiago
AU - Legnani, Delfino
AU - Stauch, Kathrin
PY - 2009/12
Y1 - 2009/12
N2 - OBJECTIVE: The GIANT study collected information on patients with acute exacerbations of chronic bronchitis (AECB) and chronic obstructive pulmonary disease (COPD) and the effect of treatment with moxifloxacin. METHODS: AECB history, concomitant diseases, moxifloxacin treatment, concomitant medication, clinical symptoms and adverse events were recorded. A questionnaire at the end of treatment recorded the impact on patients' daily lives. RESULTS: Among 9225 patients from eight European countries, marked variation was seen in characteristics including age, smoking history and type of exacerbation. Spirometry use was more common among chest physicians (66.7%) than GPs (15.5%). Patients with Anthonisen type 1 and 2 exacerbations had more frequent exacerbations and these patients experienced a greater impact on daily activities compared with patients with type 3 episodes. Patient symptoms improved with moxifloxacin treatment after a mean (SD) of 3.4 (1.8) days, allowing return to normal daily activities after 5.4 (4.4) days and with full recovery taking 6.5 (3.1) days. CONCLUSIONS: Characteristics of patients with AECB and acute exacerbations of COPD differ among European countries. Spirometry is under-used, particularly in primary care and antibiotic treatment does not always follow current guidelines. Results confirm the efficacy of moxifloxacin in the treatment of AECB in real-life conditions.
AB - OBJECTIVE: The GIANT study collected information on patients with acute exacerbations of chronic bronchitis (AECB) and chronic obstructive pulmonary disease (COPD) and the effect of treatment with moxifloxacin. METHODS: AECB history, concomitant diseases, moxifloxacin treatment, concomitant medication, clinical symptoms and adverse events were recorded. A questionnaire at the end of treatment recorded the impact on patients' daily lives. RESULTS: Among 9225 patients from eight European countries, marked variation was seen in characteristics including age, smoking history and type of exacerbation. Spirometry use was more common among chest physicians (66.7%) than GPs (15.5%). Patients with Anthonisen type 1 and 2 exacerbations had more frequent exacerbations and these patients experienced a greater impact on daily activities compared with patients with type 3 episodes. Patient symptoms improved with moxifloxacin treatment after a mean (SD) of 3.4 (1.8) days, allowing return to normal daily activities after 5.4 (4.4) days and with full recovery taking 6.5 (3.1) days. CONCLUSIONS: Characteristics of patients with AECB and acute exacerbations of COPD differ among European countries. Spirometry is under-used, particularly in primary care and antibiotic treatment does not always follow current guidelines. Results confirm the efficacy of moxifloxacin in the treatment of AECB in real-life conditions.
UR - http://www.scopus.com/inward/record.url?scp=77449133105&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77449133105&partnerID=8YFLogxK
M3 - Article
C2 - 19880426
AN - SCOPUS:77449133105
VL - 3
SP - 267
EP - 277
JO - Therapeutic Advances in Respiratory Disease
JF - Therapeutic Advances in Respiratory Disease
SN - 1753-4658
IS - 6
ER -